<DOC>
	<DOCNO>NCT02832700</DOCNO>
	<brief_summary>Casein glycomacropeptide ( CGMP ) anti-inflammatory property experimental rodent colitis use human vitro inflammation model . Its use food ingredient proven safe influence dietary intake . In pilot study investigator find , orally administer CGMP seem beneficial effect comparable mesalazine active distal ulcerative colitis . The investigator wish evaluate effect healthy subject study anti-inflammatory microbiome modulating property assess possible change gastrointestinal symptom .</brief_summary>
	<brief_title>Casein Glycomacropeptide Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Caseins</mesh_term>
	<criteria>Caucasians Body Mass Index 18.525.0 Within 3 month : Acute intestinal disease ( diarrhea 3 day week bloody stool ) , hospital admission antibiotic treatment . Chronic inflammatory disease intestinal disease , include Crohn 's disease , ulcerative colitis , celiac disease , rheumatoid arthritis autoimmune joint disease , multiple sclerosis intestinal surgery apart appendectomy . Pregnant nursing . Unable speak understand Danish .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>glycopeptides</keyword>
	<keyword>dietary protein</keyword>
	<keyword>whey protein</keyword>
	<keyword>caseinomacropeptide</keyword>
	<keyword>antiinflammatories</keyword>
	<keyword>human microbiome</keyword>
</DOC>